查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1138360

全球地中海贫血治疗市场-2022-2029

Global Thalassemia Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

地中海贫血治疗市场的增长受到多种因素的推动，例如地中海贫血患病率的增加、全球意识的提高以及研发投资的增加。

人们对地中海贫血的认识不断提高，预计将推动市场增长。

提高对地中海贫血的认识对于预防这种疾病非常重要。许多组织已经发起了宣传活动，并正在为此努力。政府也通过投资这些项目来支持这项工作。例如，庆祝 5 月 8 日国际地中海贫血日是为了提高决策者和政策制定者、医护人员、患者及其家人以及整个社区对地中海贫血的认识。大多数人对这种疾病一无所知，尤其是在亚太地区和地中海地区等流行地区。美国疾病控制和预防中心 (CDC) 正在资助一个监测血液病患者血液安全的项目。该项目被称为“与治疗性输血相关的血红蛋白疾病的并发症特征”。乔治亚大学、佛罗里达大学和加州大学旧金山分校贝尼奥夫儿童医院奥克兰分校正在研究血红蛋白疾病（镰状细胞病、地中海贫血）患者的输血相关并发症，并开发减少这些并发症的方法。有资金这样做。此外，CDC 资助公共卫生实验室协会开展筛查活动，例如实验室需求评估，以及针对患者、护理人员和卫生保健工作者的血红蛋白病筛查计划。我们提供公共卫生技术支持，例如教育。

高昂的治疗费用预计将阻碍全球地中海贫血治疗市场的增长。

高昂的治疗费用预计将阻碍全球地中海贫血治疗市场的增长。

行业分析。

《全球地中海贫血治疗市场报告》根据波特五力、创新、新产品发布、定价分析和管道分析等各种行业因素对市场进行了深入分析。

COVID-19 影响分析

COVID-19 正在对全球地中海贫血治疗市场产生重大影响。自 COVID-19 遏制协议以来，许多市场参与者的供应链被打乱，导致原材料短缺并扰乱供应链。此外，由于社会化规定，定期健康检查很困难，大多数地中海贫血患者未被发现，对大流行期间全球地中海贫血治疗市场的增长产生了负面影响。

全球地中海贫血治疗市场 - 细分分析

在整个预测期内（2022-2029 年），ALPHA-地中海贫血预计将主导地中海贫血治疗市场。

由于其在全球范围内的高流行率，预计在预测期内（2022-2029 年），ALPHA地中海贫血将占据最大的市场份额。根据美国国家罕见病组织的数据，每 1,000 名活产儿中有 4 至 20 人患有阿尔法地中海贫血症。 ALPHA地中海贫血在全世界大多数人群中都有发现，但最常见于中东、东南亚和地中海沿岸的一些国家。由于迁移增加，欧洲和北美的医生也越来越多地遇到ALPHA-地中海贫血患者。 ALPHA地中海贫血是一种遗传性疾病，由製造血红蛋白所需的基因突变引起。这些突变阻止或减少血红蛋白的产生，从而导致缺乏成熟的红细胞和贫血。导致 ALPHA 地中海贫血的突变在亚洲、印度、中东和地中海地区很常见，并且在高达 20% 的人口中发现。然而，由于现代人类的不断迁移，病例在其他地区变得越来越普遍。地中海南部国家已经认识到 ALPHA-地中海贫血患者的增加，并正在增加资源以充分满足不断增长的需求，从而导致 ALPHA-地中海贫血药物市场的全球扩张。

全球地中海贫血治疗市场报告将提供对大约 40 多个市场数据表、45 多个图表和 200 多个页面（大约）的访问。

内容

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 提高认识
      • 研发进展
    • 限制因素
      • 开发成本高
      • 治疗费用高
    • 商机
    • 影响分析

第5章行业分析

  • 波特五力分析
  • 供应链分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按疾病类型

  • 阿尔法地中海贫血
  • β地中海贫血

第 8 章按治疗类型

  • 输血
  • 铁螯合疗法
  • 骨髓移植
  • 基因治疗
  • 手术

第 9 章给药途径

  • 口语
  • 注入

第 10 章，最终用户

  • 医院和诊所
  • 其他

第 11 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 12 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准

第 13 章公司简介

  • 百时美施贵宝公司
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Vifor Pharma
  • Kiadis Pharma
  • Gamida Cell
  • ApoPharma
  • bluebird bio, Inc.
  • Novartis AG
  • Celgene Corporation,
  • La Jolla Pharmaceutical
  • Sangamo Biosciences
  • Acceleron Pharma.

第14章 DataM

简介目录
Product Code: DMPH2148

Market Overview

Thalassemia Treatment Market is expected to grow at a CAGR of 10.5% during the forecasting period (2022-2029).

Thalassemia is an inherited blood disorder that reduces the production of functional hemoglobin, the protein in red blood cells that carries oxygen. This causes a shortage of red blood cells and low oxygen levels in the bloodstream, leading to various health problems. Signs and symptoms vary but may include mild to severe anemia, paleness, fatigue, yellow discoloration of the skin, and bone problems. When there are not enough healthy red blood cells, there is also not enough oxygen delivered to all the other cells of the body, which may cause a person to feel tired, weak or short of breath. This is a condition called anemia. People with thalassemia may have mild or severe anemia. Severe anemia can damage organs and lead to death.

Market Dynamics

The thalassemia treatment market growth is driven by several factors, such as an increase in the prevalence of thalassemia, a rise in global awareness and, increasing investment in research and development.

The rising awareness about thalassemia is expected to drive market growth.

An increase in awareness about thalassemia is very important for the prevention of the disease. Many organizations are working towards this cause by initiating awareness campaigns. Governments of countries are also supporting the cause by investing in these programs. For instance, International Thalassaemia Day is celebrated on May 8 to raise awareness amongst people concerned with decision and policymaking, health care professionals, patients and their families and the community at large about thalassemia. The majority of the population is unaware of the disease, especially in more prevalent areas, such as the Asia Pacific and the Mediterranean. The Center for Disease Control and Prevention (CDC) funds one project that monitors blood safety in people with blood disorders. This project is called "Characterizing the Complications Associated with Therapeutic Blood Transfusions for Hemoglobinopathies." Georgia State University, the University of Florida, and the University of California at San Francisco Benioff Children's Hospital Oakland have been awarded funding to look at transfusion-related complications in people with hemoglobin disorders (sickle cell disease and thalassemia) and develop approaches for reducing these complications. Besides, CDC funds the Association of Public Health Laboratories to provide public health technical assistance with screening (a test to look for a disease before it is noticeable) activities, including needs assessments for laboratories, as well as education for patients, caregivers, and healthcare workers on hemoglobinopathy screening programs.

The high cost of treatment is expected to hinder global thalassemia treatment market growth.

The high cost of treatment is expected to hamper the global thalassemia treatment market growth.

Industry analysis.

The global thalassemia treatment market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing analysis, and pipeline analysis.

COVID-19 Impact Analysis

COVID-19 has significantly impacted the global Thalassemia Treatment market. Since COVID-19 containment protocols, the supply chain of many market players was disrupted and caused a lack of raw materials to disturb the supply and demand chain. Furthermore, because of the socializing restrictions, regular healthcare checkups were difficult, leaving most patients with thalassemia undetected, negatively impacting the global Thalassemia Treatment market growth during the pandemic.

Global Thalassemia Treatment Market - Segment Analysis

The alpha-thalassemia is expected to dominate the thalassemia treatment market throughout the forecast period (2022-2029)

Alpha thalassemia is expected to hold the largest market share over the period forecast (2022-2029) owning to a higher prevalence of the disease globally. According to National Organization for Rare Disorders, alpha thalassemia occurs in 4-20 individuals per every 1,000 births. Alpha thalassemia is found in most populations worldwide but is most common in the Middle East, Southeast Asia, and certain Mediterranean countries. Doctors in Europe and North America are also increasingly encountering patients with alpha-thalassemia due to increased migration. Alpha-thalassemia is an inherited disease caused by mutations in a gene required for making a component of hemoglobin. Those mutations either prevent or reduce the production of hemoglobin, which can cause a shortage of mature red blood cells and lead to anemia. The mutations that cause alpha-thalassemia are more common in Asia, India, the Middle East and the Mediterranean where they are found in up to 20% of the population. But the increase in modern migration means that cases are now cropping up more often in other regions. Southern Mediterranean countries recognize the rise in patients with alpha-thalassemia and have increased resources to meet the growing demand appropriately, hence increasing the market for alpha-thalassemia treatment globally.

Geographical Analysis

The North American region holds the largest market share of the global thalassemia treatment market.

North America is dominating the thalassemia treatment market in 2018 and is estimated to hold the largest market size over the forecast period (2022-2029), owing to an increase in thalassemia incidences, highly aware population, advanced healthcare infrastructure and favorable government initiatives. The cases of thalassemia disorder are increasing in the region due to migration. Thalassemia, once a rarity in the US, is increasingly encountered in clinical practice due to shifts in immigration. Thalassemia is becoming more prevalent in the US due to the immigration of people from affected regions; according to Cooley's Anemia Foundation, 12% of patients with B-thalassemia in their US patient database were adopted from other countries. Furthermore, many organizations and societies are working in this region to spread awareness about thalassemia and ensure its dominance over the global market.

Competitive Landscape

Some of the major key players in the market are Vifor Pharma, Kiadis Pharma, Gamida Cell, ApoPharma, bluebird bio, Inc., Novartis AG, Bristol-Myers Squibb Company, Celgene Corporation, La Jolla Pharmaceutical, Sangamo Biosciences, and Acceleron Pharma. In the thalassemia treatment market, bluebird bio-Inc. will dominate the market, owning to portfolio expansion, mergers, collaborations, and acquisitions. The key players are adopting various growth strategies such as mergers & acquisitions, partnerships, and collaborations and increasing research and development and high investment, which are contributing to the growth of the thalassemia treatment market globally. For instance, on April 16, 2021, Sanofi acquired Kiadis. Also, on December 22, 2021, Novartis acquired Gyroscope Therapeutics.

Bristol-Myers Squibb Company

Overview:

The Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York City. BMS is a leading pharmaceutical company and has consistently ranked among the largest U.S. corporations. For fiscal 2021, it had total revenue of $46.4 billion.

Product Portfolio:

The product portfolio of Bristol-Myers Squibb Company for thalassemia treatment contains REBLOZYL.

The global thalassemia treatment market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Awareness
      • 4.1.1.2. Research and Development
    • 4.1.2. Restraints
      • 4.1.2.1. The High Development Cost
      • 4.1.2.2. High Treatment Cost
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment
    • 7.1.2. Market Attractiveness Index, By Disease Type Segment
  • 7.2. Alpha Thalassemia
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Beta Thalassemia

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment
    • 8.1.2. Market Attractiveness Index, By Treatment Type Segment
  • 8.2. Blood Transfusion
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Iron Chelation Therapy
  • 8.4. Bone Marrow Transplant
  • 8.5. Gene Therapy
  • 8.6. Surgery

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration Segment
    • 9.1.2. Market Attractiveness Index, By Route of administration Segment
  • 9.2. Oral
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Injectable

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User Segment
  • 10.2. Hospitals and Clinics
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Other

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. The U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. The U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking

13. Company Profiles

  • 13.1. Bristol-Myers Squibb Company
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Vifor Pharma
  • 13.3. Kiadis Pharma
  • 13.4. Gamida Cell
  • 13.5. ApoPharma
  • 13.6. bluebird bio, Inc.
  • 13.7. Novartis AG
  • 13.8. Celgene Corporation,
  • 13.9. La Jolla Pharmaceutical
  • 13.10. Sangamo Biosciences
  • 13.11. Acceleron Pharma.

LIST NOT EXHAUSTIVE

14. DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us